Clinical implementation of targeted and immunotherapies for advanced RCC

Episode 1 December 14, 2022 00:19:51
Clinical implementation of targeted and immunotherapies for advanced RCC
COR2ED Medical Education
Clinical implementation of targeted and immunotherapies for advanced RCC

Dec 14 2022 | 00:19:51

/

Show Notes

Prof. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Dr Friederike Schlürmann a Medical Oncologist from University Hospital of Brest and Quimper in France, discuss the clinical implementation of targeted and immunotherapies for advanced renal cell carcinoma (RCC).

In this podcast, the two experts discuss data from key trials CHECKMATE 214 (ipilimumab and nivolumab), KEYNOTE 426 (axitinib and pembrolizumab), CHECKMATE 9ER (cabozantinib and nivolumab), CLEAR (Lenvatinib and pembrolizumab) and COSMIC 313 (cabozantinib plus nivolumab and ipilimumab) and the implications for clinical practice.

They also discuss management of toxicities associated with combination treatments, including dosing strategies to ensure the patient remains on optimal treatment and improved education for patients and clinicians so that they recognise side effects and how to manage them.

Other Episodes

Episode 1

August 17, 2022 00:29:42
Episode Cover

Role of immunotherapy beyond advanced HCC

COR2ED Medical Education: In this podcast, liver cancer experts Prof. Amit Singal and Assoc. Prof Neil Mehta discuss recent advances in systemic and locoregional...

Listen

Episode 2

February 07, 2022 00:24:43
Episode Cover

PARP inhibitors in prostate cancer: What nurses need to know

COR2ED Medical Education: Pablo Peinado, Research Nurse Coordinator, and Dr. Elena Castro, medical oncologist, who both work at Hospital Universitario Virgen de la Victoria...

Listen

Episode 21

September 03, 2023 00:29:25
Episode Cover

Advanced HCC: 2nd line treatment selection and the right time to switch

COR2ED Medical Education: Prof. Dr Amit Singal, Gastroenterologist and Hepatologist at UT Southwestern Medical Center, USA and Prof. Dr Jeroen Dekervel, GI Oncologist at...

Listen